CN107739338A - 作为辣椒素类似物受体配体的甲酰胺及脲衍生物 - Google Patents

作为辣椒素类似物受体配体的甲酰胺及脲衍生物 Download PDF

Info

Publication number
CN107739338A
CN107739338A CN201710970447.5A CN201710970447A CN107739338A CN 107739338 A CN107739338 A CN 107739338A CN 201710970447 A CN201710970447 A CN 201710970447A CN 107739338 A CN107739338 A CN 107739338A
Authority
CN
China
Prior art keywords
phenyl
methyl
pyrazol
fluoro
mmol
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Pending
Application number
CN201710970447.5A
Other languages
English (en)
Chinese (zh)
Inventor
R.弗兰克-福尔蒂恩
T.克里斯托弗
K.希内
J.德夫里
N.达曼
B.莱施
G.巴伦贝格
D.J.绍恩德斯
H.施托克豪森
金勇洙
金明燮
李智雨
Current Assignee (The listed assignees may be inaccurate. Google has not performed a legal analysis and makes no representation or warranty as to the accuracy of the list.)
MEDIFRON DBT CO Ltd
Original Assignee
MEDIFRON DBT CO Ltd
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by MEDIFRON DBT CO Ltd filed Critical MEDIFRON DBT CO Ltd
Publication of CN107739338A publication Critical patent/CN107739338A/zh
Pending legal-status Critical Current

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D231/00—Heterocyclic compounds containing 1,2-diazole or hydrogenated 1,2-diazole rings
    • C07D231/02—Heterocyclic compounds containing 1,2-diazole or hydrogenated 1,2-diazole rings not condensed with other rings
    • C07D231/10—Heterocyclic compounds containing 1,2-diazole or hydrogenated 1,2-diazole rings not condensed with other rings having two or three double bonds between ring members or between ring members and non-ring members
    • C07D231/12—Heterocyclic compounds containing 1,2-diazole or hydrogenated 1,2-diazole rings not condensed with other rings having two or three double bonds between ring members or between ring members and non-ring members with only hydrogen atoms, hydrocarbon or substituted hydrocarbon radicals, directly attached to ring carbon atoms
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P1/00—Drugs for disorders of the alimentary tract or the digestive system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P11/00—Drugs for disorders of the respiratory system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P13/00—Drugs for disorders of the urinary system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P15/00—Drugs for genital or sexual disorders; Contraceptives
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P17/00—Drugs for dermatological disorders
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P19/00—Drugs for skeletal disorders
    • A61P19/02—Drugs for skeletal disorders for joint disorders, e.g. arthritis, arthrosis
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P19/00—Drugs for skeletal disorders
    • A61P19/08—Drugs for skeletal disorders for bone diseases, e.g. rachitism, Paget's disease
    • A61P19/10—Drugs for skeletal disorders for bone diseases, e.g. rachitism, Paget's disease for osteoporosis
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P23/00—Anaesthetics
    • A61P23/02—Local anaesthetics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P27/00—Drugs for disorders of the senses
    • A61P27/02—Ophthalmic agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P29/00—Non-central analgesic, antipyretic or antiinflammatory agents, e.g. antirheumatic agents; Non-steroidal antiinflammatory drugs [NSAID]
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P3/00—Drugs for disorders of the metabolism
    • A61P3/04—Anorexiants; Antiobesity agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
    • A61P31/12—Antivirals
    • A61P31/20—Antivirals for DNA viruses
    • A61P31/22—Antivirals for DNA viruses for herpes viruses
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P37/00—Drugs for immunological or allergic disorders
    • A61P37/08—Antiallergic agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P7/00—Drugs for disorders of the blood or the extracellular fluid
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P7/00—Drugs for disorders of the blood or the extracellular fluid
    • A61P7/10—Antioedematous agents; Diuretics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P9/00—Drugs for disorders of the cardiovascular system
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D405/00—Heterocyclic compounds containing both one or more hetero rings having oxygen atoms as the only ring hetero atoms, and one or more rings having nitrogen as the only ring hetero atom
    • C07D405/02—Heterocyclic compounds containing both one or more hetero rings having oxygen atoms as the only ring hetero atoms, and one or more rings having nitrogen as the only ring hetero atom containing two hetero rings
    • C07D405/12—Heterocyclic compounds containing both one or more hetero rings having oxygen atoms as the only ring hetero atoms, and one or more rings having nitrogen as the only ring hetero atom containing two hetero rings linked by a chain containing hetero atoms as chain links
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D407/00—Heterocyclic compounds containing two or more hetero rings, at least one ring having oxygen atoms as the only ring hetero atoms, not provided for by group C07D405/00
    • C07D407/02—Heterocyclic compounds containing two or more hetero rings, at least one ring having oxygen atoms as the only ring hetero atoms, not provided for by group C07D405/00 containing two hetero rings
    • C07D407/12—Heterocyclic compounds containing two or more hetero rings, at least one ring having oxygen atoms as the only ring hetero atoms, not provided for by group C07D405/00 containing two hetero rings linked by a chain containing hetero atoms as chain links

Landscapes

  • Health & Medical Sciences (AREA)
  • Organic Chemistry (AREA)
  • Chemical & Material Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • General Chemical & Material Sciences (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Animal Behavior & Ethology (AREA)
  • General Health & Medical Sciences (AREA)
  • Public Health (AREA)
  • Veterinary Medicine (AREA)
  • Engineering & Computer Science (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Rheumatology (AREA)
  • Physical Education & Sports Medicine (AREA)
  • Diabetes (AREA)
  • Hematology (AREA)
  • Virology (AREA)
  • Orthopedic Medicine & Surgery (AREA)
  • Anesthesiology (AREA)
  • Pulmonology (AREA)
  • Immunology (AREA)
  • Biotechnology (AREA)
  • Neurosurgery (AREA)
  • Child & Adolescent Psychology (AREA)
  • Obesity (AREA)
  • Ophthalmology & Optometry (AREA)
  • Pain & Pain Management (AREA)
  • Cardiology (AREA)
  • Biomedical Technology (AREA)
  • Neurology (AREA)
  • Oncology (AREA)
  • Communicable Diseases (AREA)
  • Molecular Biology (AREA)
  • Heart & Thoracic Surgery (AREA)
  • Dermatology (AREA)
  • Endocrinology (AREA)
  • Reproductive Health (AREA)
CN201710970447.5A 2011-11-09 2012-11-08 作为辣椒素类似物受体配体的甲酰胺及脲衍生物 Pending CN107739338A (zh)

Applications Claiming Priority (3)

Application Number Priority Date Filing Date Title
EP11008914.1 2011-11-09
EP11008914 2011-11-09
CN201280053470.3A CN103889961A (zh) 2011-11-09 2012-11-08 作为辣椒素类似物受体配体的携带被含氧基团取代的苯基的被取代的基于吡唑基的甲酰胺及脲衍生物

Related Parent Applications (1)

Application Number Title Priority Date Filing Date
CN201280053470.3A Division CN103889961A (zh) 2011-11-09 2012-11-08 作为辣椒素类似物受体配体的携带被含氧基团取代的苯基的被取代的基于吡唑基的甲酰胺及脲衍生物

Publications (1)

Publication Number Publication Date
CN107739338A true CN107739338A (zh) 2018-02-27

Family

ID=47143122

Family Applications (2)

Application Number Title Priority Date Filing Date
CN201710970447.5A Pending CN107739338A (zh) 2011-11-09 2012-11-08 作为辣椒素类似物受体配体的甲酰胺及脲衍生物
CN201280053470.3A Pending CN103889961A (zh) 2011-11-09 2012-11-08 作为辣椒素类似物受体配体的携带被含氧基团取代的苯基的被取代的基于吡唑基的甲酰胺及脲衍生物

Family Applications After (1)

Application Number Title Priority Date Filing Date
CN201280053470.3A Pending CN103889961A (zh) 2011-11-09 2012-11-08 作为辣椒素类似物受体配体的携带被含氧基团取代的苯基的被取代的基于吡唑基的甲酰胺及脲衍生物

Country Status (14)

Country Link
EP (1) EP2776398B1 (enExample)
JP (1) JP6189313B2 (enExample)
KR (1) KR101985442B1 (enExample)
CN (2) CN107739338A (enExample)
AR (1) AR088702A1 (enExample)
AU (1) AU2012334065B2 (enExample)
BR (1) BR112014011262B1 (enExample)
CA (1) CA2854932A1 (enExample)
ES (1) ES2823577T3 (enExample)
HK (1) HK1201839A1 (enExample)
IN (1) IN2014KN00849A (enExample)
MX (1) MX2014005610A (enExample)
TW (1) TW201326133A (enExample)
WO (1) WO2013068461A1 (enExample)

Families Citing this family (4)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
WO2016096140A1 (en) * 2014-12-19 2016-06-23 Grünenthal GmbH Process for the preparation of 1-[(heteroaryl)-methyl]- or 1-[(aryl)-methyl]-3-[4-(hydroxymethyl)-phenyl]-ureas
JPWO2017170884A1 (ja) * 2016-03-31 2019-02-14 富士フイルム富山化学株式会社 新規なヒドロキサム酸誘導体の製造方法およびその中間体
KR102722412B1 (ko) * 2017-05-19 2024-10-30 에트나-텍 리미티드 기능화 플루오르화 단량체의 제조방법, 플루오르화 단량체 및 그 제조용 조성물
CN113135856B (zh) * 2021-04-08 2022-10-11 天津大学 一类3-三氟甲基-5-氰基吡唑化合物及其制备方法

Citations (3)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
WO2007045462A2 (de) * 2005-10-19 2007-04-26 Grünenthal GmbH Neue vanilloid-rezeptor liganden und ihre verwendung zur herstellung von arzneimitteln
CN101687799A (zh) * 2007-04-16 2010-03-31 格吕伦塔尔有限公司 新的香草素受体配体及其在制备药物中的用途
WO2010127856A1 (en) * 2009-05-07 2010-11-11 Grünenthal GmbH Substituted phenyllureas and phenylamides as vanilloid receptor ligands

Family Cites Families (6)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
WO1999012910A1 (en) * 1997-09-11 1999-03-18 Nissan Chemical Industries, Ltd. Pyrazole compounds and plant disease control agent
US20050267182A1 (en) * 2003-11-13 2005-12-01 Ambit Biosciences Corporation Urea derivatives as FLT-3 modulators
JP2005314407A (ja) * 2004-03-31 2005-11-10 Nippon Nohyaku Co Ltd 新規なハロアルキルスルホンアニリド誘導体、除草剤及びその使用方法並びにその中間体
CN101679297B (zh) * 2006-12-08 2012-01-11 埃克塞利希斯股份有限公司 Lxr和fxr调节剂
BRPI1011192A2 (pt) 2009-05-07 2016-03-15 Gruenenthal Gmbh derivados de carboxamida e ureia aromáticas substituídas como ligantes de receptor de vaniloide, composição farmacêutica, uso e processo para preparação dos referidos derivados
WO2011109441A1 (en) * 2010-03-01 2011-09-09 Myrexis, Inc. Compounds and therapeutic uses thereof

Patent Citations (3)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
WO2007045462A2 (de) * 2005-10-19 2007-04-26 Grünenthal GmbH Neue vanilloid-rezeptor liganden und ihre verwendung zur herstellung von arzneimitteln
CN101687799A (zh) * 2007-04-16 2010-03-31 格吕伦塔尔有限公司 新的香草素受体配体及其在制备药物中的用途
WO2010127856A1 (en) * 2009-05-07 2010-11-11 Grünenthal GmbH Substituted phenyllureas and phenylamides as vanilloid receptor ligands

Non-Patent Citations (2)

* Cited by examiner, † Cited by third party
Title
DEVIN M. SWANSON ET AL.: ""Identification and Biological Evaluation of 4-(3-Trifluoromethylpyridin-2-yl)piperazine-1-carboxylic Acid (5-Trifluoromethylpyridin-2-yl)amide, a High Affinity TRPV1 (VR1) Vanilloid Receptor Antagonist"", 《J. MED. CHEM.》 *
戴冬艳等: ""治疗疼痛新途径:瞬时受体电位香草酸亚型1拮抗剂的研究进展"", 《中国药科大学学报》 *

Also Published As

Publication number Publication date
CN103889961A (zh) 2014-06-25
KR20140091043A (ko) 2014-07-18
AU2012334065B2 (en) 2017-06-08
ES2823577T3 (es) 2021-05-07
KR101985442B1 (ko) 2019-06-03
BR112014011262A8 (pt) 2018-03-06
EP2776398B1 (en) 2020-09-02
AU2012334065A1 (en) 2014-05-22
TW201326133A (zh) 2013-07-01
BR112014011262B1 (pt) 2022-02-15
IN2014KN00849A (enExample) 2015-10-02
BR112014011262A2 (pt) 2017-04-25
JP6189313B2 (ja) 2017-08-30
WO2013068461A1 (en) 2013-05-16
AR088702A1 (es) 2014-06-25
EP2776398A1 (en) 2014-09-17
HK1201839A1 (en) 2015-09-11
MX2014005610A (es) 2014-07-30
JP2014532741A (ja) 2014-12-08
CA2854932A1 (en) 2013-05-16

Similar Documents

Publication Publication Date Title
US9624209B2 (en) Substituted phenylureas and phenylamides as vanilloid receptor ligands
JP5745505B2 (ja) バニロイド受容体リガンドとしての置換フェニル尿素および置換フェニルアミド
JP5767631B2 (ja) バニロイド受容体リガンドとしての置換された芳香族カルボキサミドおよび尿素誘導体
CN102307622B (zh) 用于治疗癌症和免疫和自身免疫疾病的诱发细胞凋亡的药剂
WO2020114482A1 (zh) 一类异吲哚啉类化合物、其制备方法、药物组合物及其应用
CN102164920B (zh) 烷基噻唑氨基甲酸酯衍生物、其制备方法和其作为faah酶抑制剂的用途
CN1100773C (zh) 苯并呋喃羧酸胺和磺酰胺
CN108699015A (zh) 对电压门控性钠通道具有选择性活性的羟基烷基胺-和羟基环烷基胺-取代的二胺-芳基磺胺化合物
WO2018145621A1 (zh) 喹啉类化合物、其制备方法及其医药用途
JP2013534229A (ja) バニロイド受容体リガンドとしての置換された環状カルボキサミド誘導体および尿素誘導体
JP2014532746A (ja) バニロイド受容体リガンドとしての、ｃｏ含有基で置換されたフェニル部分を担持する置換ピラゾリルをベースとするカルボキサミドおよび尿素誘導体
JP6189313B2 (ja) バニロイド受容体リガンドとしての、ｏ含有基で置換されたフェニル部分を担持する置換ピラゾリルをベースとするカルボキサミドおよび尿素誘導体
KR20150085045A (ko) 3-아미노시클로펜탄 카르복사미드 유도체
CN103906734A (zh) 被取代的甲磺酰胺衍生物作为类香草素受体配体
JP2014532744A (ja) バニロイド受容体リガンドとしての、ｓｏ２含有基で置換されたフェニル部分を担持する置換ピラゾリルをベースとするカルボキサミドおよび尿素誘導体
JP2014532742A (ja) バニロイド受容体リガンドとしての、ｎ含有基で置換されたフェニル部分を担持する置換ピラゾリルをベースとするカルボキサミドおよび尿素誘導体
JP2014532743A (ja) バニロイド受容体リガンドとしての、ｎ−環式基で置換されたフェニル部分を担持する置換ピラゾリルをベースとするカルボキサミドおよび尿素誘導体
HK1117152A1 (en) Triazole substituted aminobenzophenone compounds
HK1117152B (en) Triazole substituted aminobenzophenone compounds

Legal Events

Date Code Title Description
PB01 Publication
PB01 Publication
SE01 Entry into force of request for substantive examination
SE01 Entry into force of request for substantive examination
WD01 Invention patent application deemed withdrawn after publication
WD01 Invention patent application deemed withdrawn after publication

Application publication date: 20180227